Impact of the STK11/KRAS co-mutation on the response to immunotherapy in a real-world pan-cancer cohort

CONCLUSIONS: Co-mutation STK11/KRAS is common among patients with non-small cell lung cancer and is not an independent predictive marker for the efficacy of immune checkpoint inhibitors. Further studies are required to clarify the role of STK11 mutations in immune checkpoint inhibitor treatment response.PMID:37817679 | DOI:10.1177/03008916231204441

Source: Tumori - October 11, 2023 Category: Cancer & Oncology Authors: Andrea Olsen Alexandra Lebedeva Polina Nosova Vladislav Nikulin Margarita Sharova Ekaterina Ignatova Vladislav Mileyko Maxim Ivanov Source Type: research